Closed · RFA-OD-20-014 · CFDA 93.213;93.233;93.273;93.310;93.393;93.394;93.396;93.399;93.837;93.838;93.839;93.840;93.865;93.866 · Discretionary
Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $300K
- Award range
- Closed
- Status
- September 15, 2020
- Close date
- 10
- Expected awards
The verdict
Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $300,000 across 10 expected awards. Future funding cycles may be published under the same CFDA number.
- up to $300K
- award range
- Closed
- application status
- 10
- expected awards
- 93.213;93.233;93.273;93.310;93.393;93.394;93.396;93.399;93.837;93.838;93.839;93.840;93.865;93.866
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed) - is cataloged under number RFA-OD-20-014 and tied to CFDA assistance listing 93.213;93.233;93.273;93.310;93.393;93.394;93.396;93.399;93.837;93.838;93.839;93.840;93.865;93.866, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on August 6, 2020. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is Up to $300,000. The agency has projected $10.0 million in total estimated funding for this announcement. It expects to issue 10 awards. If the agency funds the expected 10 awards from the $10.0 million estimated pool, the average award works out to roughly $1.0 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on September 15, 2020. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Up to $300,000
Close Date
September 15, 2020
Posted
August 6, 2020
Est. Total Funding
$10,000,000
Expected Awards
10
Instrument
Cooperative Agreement
Description
NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit proposals for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, this RFA will support the early stage development of an innovative platform that integrates aptamer biosensing with touchscreen or other digital devices to achieve real-time detection and tracing of SARS-CoV-2. The project needs to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, immobilized sensor functionality, automatic signal transduction and detection by digital devices. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH expects that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the Data Coordinating Center (DCC) funding opportunity
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |